CDRH Pre-Market Reform Proposals Expected Within Weeks
This article was originally published in The Gray Sheet
Executive Summary
The FDA device center's upcoming proposals for reforming its pre-market policies will directly address widespread industry concern that reviews are increasingly unpredictable and opaque, CDRH Director Jeff Shuren told an industry audience last week
You may also be interested in...
Broad 510(k) Reform Still On The Table; IOM Panel Enters Closed-Door Phase
The Institute of Medicine committee charged with recommending reforms to FDA's 510(k) clearance program will move the remainder of its efforts behind closed doors
Broad 510(k) Reform Still On The Table; IOM Panel Enters Closed-Door Phase
The Institute of Medicine committee charged with recommending reforms to FDA's 510(k) clearance program will move the remainder of its efforts behind closed doors
Unmet Medical Needs, Regulatory Barriers Addressed In Public Comments
Device makers list drug-therapy monitoring tests, venous disease and diabetes treatments, and products targeting children and rare diseases among the top unmet public health priorities for FDA and other government agencies